Dry eye disease affects millions of people in the U.S., and while several treatments, mostly eye drops, are available, they all have flaws. An emerging startup called Oyster Point Pharmaceuticals is trying a completely different approach—a nasal spray that coaxes the body into making tears. And the company just got enough cash to get that treatment to market, if its final clinical tests are a success.
Oyster Point, a Princeton, NJ startup led by former Ophthotech (NASDAQ: OPHT) executive Jeffrey Nau, has closed a $93 million Series B co-led by Invus and Flying L Partners.
The cash will help bankroll… Read more »